Zishan Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zishan Yang has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
Shenglan Zhang
Xinxiang Key Laboratory of Tumor Vaccine and Immunotherapy, School of Basic Medical Sciences, Henan Medical University
2 shared publicationsTiesuo Zhao
2 shared publicationsAiping Sun
Department of Immunology, School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, China
1 shared publicationAnna Zheng
Xinxiang Key Laboratory of Tumor Vaccine and Immunotherapy, School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, Henan 453003, PR China; Henan Research Center for Engineering Technology in Digestive Tract Tumor Immune Digital Decoding and Cell Therapy, Xinxiang Medical University, Xinxiang, Henan 453000, PR China
1 shared publicationAoyuan Fan
Xinxiang Engineering Technology Research Center of Immune Checkpoint Drug for Liver-Intestinal Tumors, Xinxiang Medical University, Xinxiang, Henan 453000, PR China; Xinxiang Key Laboratory of Tumor Vaccine and Immunotherapy, Xinxiang Medical University, Xinxiang, Henan 453000, PR China
1 shared publication- Chao Lei
Department of Surgery, Division of Immunotherapy, University of Louisville, Louisville, USA
1 shared publication
Latest Publications
- Open Access
- 24 August 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (9) , 1226
Intestinal Fucosylation: A Key Regulatory Hub in Homeostasis and Disease Pathogenesis
Inflammatory bowel disease (IBD) and colorectal cancer (CRC) are heterogeneous intestinal disorders that pose significant threats to human health and share common pathological features, including intestinal mucosal barrier disruption and gut microbiota dysbiosis, in which fucosylation acts as a critical regulatory mediator. Fucosylation is a highly conserved post-translational glycosylation modification involving the enzymatic transfer of fucose residues to glycoproteins and glycolipids. This tightly regulated process plays essential roles in maintaining intestinal homeostasis, mediating host–microbiota interactions and regulating immune responses. This review adopts a physiology-to-pathology framework, delineating fucosylation’s operational principles in healthy intestines and its dysregulation in IBD and CRC. It summarizes the spatial distribution of fucosylation, its regulatory mechanisms, and its roles in disease pathogenesis, and also discusses its potential as a diagnostic biomarker and therapeutic target. Finally, this review highlights future research directions to bridge mechanistic insights with clinical translation, emphasizing the promise of fucosylation in the precision diagnosis and treatment of intestinal disorders.
- 24 August 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (9) , 1226
Open AccessIntestinal Fucosylation: A Key Regulatory Hub in Homeostasis and Disease Pathogenesis
Inflammatory bowel disease (IBD) and colorectal cancer (CRC) are heterogeneous intestinal disorders that pose significant threats to human health and share common pathological features, including intestinal mucosal barrier disruption and gut microbiota dysbiosis, in which fucosylation acts as a critical regulatory mediator. Fucosylation is a highly conserved post-translational glycosylation modification involving the enzymatic transfer of fucose residues to glycoproteins and glycolipids. This tightly regulated process plays essential roles in maintaining intestinal homeostasis, mediating host–microbiota interactions and regulating immune responses. This review adopts a physiology-to-pathology framework, delineating fucosylation’s operational principles in healthy intestines and its dysregulation in IBD and CRC. It summarizes the spatial distribution of fucosylation, its regulatory mechanisms, and its roles in disease pathogenesis, and also discusses its potential as a diagnostic biomarker and therapeutic target. Finally, this review highlights future research directions to bridge mechanistic insights with clinical translation, emphasizing the promise of fucosylation in the precision diagnosis and treatment of intestinal disorders.
- Open Access
- 15 April 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1699470
Integrated bioinformatics and machine learning identify early diagnostic biomarkers for MAFLD with comorbid psoriasis
Background: Psoriasis and metabolic dysfunction–associated fatty liver disease (MAFLD) share pathological features such as chronic inflammation, immune dysregulation, and metabolic disturbance. Increasing evidence suggests biological crosstalk between the two conditions, offering new insights into their shared mechanisms and comanagement. Early-stage MAFLD, characterized by hepatic steatosis without evident inflammation or fibrosis, provides a crucial window for intervention. This study aimed to identify early diagnostic biomarkers linking psoriasis and MAFLD. Methods: Transcriptomic datasets of psoriasis and MAFLD were retrieved from the Gene Expression Omnibus (GEO) database. Weighted gene co-expression network analysis (WGCNA) was used to identify MAFLD-related modules. Shared genes were obtained by intersecting module genes with differentially expressed genes (DEGs) from psoriasis datasets. Machine learning algorithms, including random forest (RF), least absolute shrinkage and selection operator (LASSO), and support vector machine (SVM), were applied to identify hub genes. Diagnostic performance was evaluated using receiver operating characteristic (ROC) analysis, immune infiltration assessment, Spearman correlation, and experimental validation in psoriasis and MAFLD mouse models. Results: Twenty-nine shared genes were identified and found to be enriched in immune and metabolic pathways. Six hub genes—ADRB2, WNT5A, S100A9, FAM110C, S100A12, and TUBB6—were selected through integrated machine learning analysis and experimental validation. These genes exhibited high diagnostic accuracy and significant correlations with disease severity and immune cell infiltration. Conclusions: This study identified six hub genes—ADRB2, WNT5A, S100A9, FAM110C, S100A12, and TUBB6—as potential cross-disease biomarkers for the comorbidity of psoriasis and MAFLD, and these genes are significantly associated with disease severity. These findings provide new targets for early diagnosis and potential treatment strategies for the comorbidity.
- 15 April 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1699470
Open AccessIntegrated bioinformatics and machine learning identify early diagnostic biomarkers for MAFLD with comorbid psoriasis
Background: Psoriasis and metabolic dysfunction–associated fatty liver disease (MAFLD) share pathological features such as chronic inflammation, immune dysregulation, and metabolic disturbance. Increasing evidence suggests biological crosstalk between the two conditions, offering new insights into their shared mechanisms and comanagement. Early-stage MAFLD, characterized by hepatic steatosis without evident inflammation or fibrosis, provides a crucial window for intervention. This study aimed to identify early diagnostic biomarkers linking psoriasis and MAFLD. Methods: Transcriptomic datasets of psoriasis and MAFLD were retrieved from the Gene Expression Omnibus (GEO) database. Weighted gene co-expression network analysis (WGCNA) was used to identify MAFLD-related modules. Shared genes were obtained by intersecting module genes with differentially expressed genes (DEGs) from psoriasis datasets. Machine learning algorithms, including random forest (RF), least absolute shrinkage and selection operator (LASSO), and support vector machine (SVM), were applied to identify hub genes. Diagnostic performance was evaluated using receiver operating characteristic (ROC) analysis, immune infiltration assessment, Spearman correlation, and experimental validation in psoriasis and MAFLD mouse models. Results: Twenty-nine shared genes were identified and found to be enriched in immune and metabolic pathways. Six hub genes—ADRB2, WNT5A, S100A9, FAM110C, S100A12, and TUBB6—were selected through integrated machine learning analysis and experimental validation. These genes exhibited high diagnostic accuracy and significant correlations with disease severity and immune cell infiltration. Conclusions: This study identified six hub genes—ADRB2, WNT5A, S100A9, FAM110C, S100A12, and TUBB6—as potential cross-disease biomarkers for the comorbidity of psoriasis and MAFLD, and these genes are significantly associated with disease severity. These findings provide new targets for early diagnosis and potential treatment strategies for the comorbidity.
- Open Access
- 29 October 2025
- Published by Elsevier in International Immunopharmacology
- Vol. 167, 115755
IL-27 gut immunology: Mechanisms and potential value as a biomarker and therapeutic target in intestinal diseases
- 29 October 2025
- Published by Elsevier in International Immunopharmacology
- Vol. 167, 115755
Open AccessIL-27 gut immunology: Mechanisms and potential value as a biomarker and therapeutic target in intestinal diseases
- 4 July 2025
- Published by Elsevier in Biochemical Pharmacology
- Vol. 240, 117103
Enhanced antitumor immune response in melanoma-bearing mice via attenuated Salmonella carrying an IL-21-shRNA-CCR2 co-expression plasmid
- 4 July 2025
- Published by Elsevier in Biochemical Pharmacology
- Vol. 240, 117103
Enhanced antitumor immune response in melanoma-bearing mice via attenuated Salmonella carrying an IL-21-shRNA-CCR2 co-expression plasmid
- Open Access
- 9 September 2024
- Published by Springer Nature in Microbial Cell Factories
- Vol. 23 (1) , 1-14
Immunogenicity and protective efficacy of a recombinant lactococcus lactis vaccine against HSV-1 infection
Herpes simplex virus type 1 (HSV-1) is a major cause of viral encephalitis, genital mucosal infections, and neonatal infections. Lactococcus lactis (L. lactis) has been proven to be an effective vehicle for delivering protein antigens and stimulating both mucosal and systemic immune responses. In this study, we constructed a recombinant L. lactis system expressing the protective antigen glycoprotein D (gD) of HSV-1. To improve the stability and persistence of antigen stimulation of the local mucosa, we inserted the immunologic adjuvant interleukin (IL)-2 and the Fc fragment of IgG into the expression system, and a recombinant L. lactis named NZ3900-gD-IL-2-Fc was constructed. By utilizing this recombinant L. lactis strain to elicit an immune response and evaluate the protective effect in mice, the recombinant L. lactis vaccine induced a significant increase in specific neutralizing antibodies, IgG, IgA, interferon-γ, and IL-4 levels in the serum of mice. Furthermore, in comparison to the mice in the control group, the vaccine also enhanced the proliferation levels of lymphocytes in response to gD. Moreover, recombinant L. lactis expressing gD significantly boosted nonspecific immune reactions in mice through the activation of immune-related genes. Furthermore, following the HSV-1 challenge of the murine lung mucosa, mice inoculated with the experimental vaccine exhibited less lung damage than control mice. Our study presents a novel method for constructing a recombinant vaccine using the food-grade, non-pathogenic, and non-commercial bacterium L. lactis. The findings indicate that this recombinant vaccine shows promise in preventing HSV-1 infection in mice.
- 9 September 2024
- Published by Springer Nature in Microbial Cell Factories
- Vol. 23 (1) , 1-14
Open AccessImmunogenicity and protective efficacy of a recombinant lactococcus lactis vaccine against HSV-1 infection
Herpes simplex virus type 1 (HSV-1) is a major cause of viral encephalitis, genital mucosal infections, and neonatal infections. Lactococcus lactis (L. lactis) has been proven to be an effective vehicle for delivering protein antigens and stimulating both mucosal and systemic immune responses. In this study, we constructed a recombinant L. lactis system expressing the protective antigen glycoprotein D (gD) of HSV-1. To improve the stability and persistence of antigen stimulation of the local mucosa, we inserted the immunologic adjuvant interleukin (IL)-2 and the Fc fragment of IgG into the expression system, and a recombinant L. lactis named NZ3900-gD-IL-2-Fc was constructed. By utilizing this recombinant L. lactis strain to elicit an immune response and evaluate the protective effect in mice, the recombinant L. lactis vaccine induced a significant increase in specific neutralizing antibodies, IgG, IgA, interferon-γ, and IL-4 levels in the serum of mice. Furthermore, in comparison to the mice in the control group, the vaccine also enhanced the proliferation levels of lymphocytes in response to gD. Moreover, recombinant L. lactis expressing gD significantly boosted nonspecific immune reactions in mice through the activation of immune-related genes. Furthermore, following the HSV-1 challenge of the murine lung mucosa, mice inoculated with the experimental vaccine exhibited less lung damage than control mice. Our study presents a novel method for constructing a recombinant vaccine using the food-grade, non-pathogenic, and non-commercial bacterium L. lactis. The findings indicate that this recombinant vaccine shows promise in preventing HSV-1 infection in mice.